News headlines about Sol Gel Technologies (NASDAQ:SLGL) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sol Gel Technologies earned a news impact score of 0.08 on Accern’s scale. Accern also gave news articles about the company an impact score of 44.1381376366377 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Several analysts recently issued reports on SLGL shares. JMP Securities started coverage on Sol Gel Technologies in a report on Monday, February 26th. They issued a “market outperform” rating and a $20.00 price target for the company. BMO Capital Markets began coverage on Sol Gel Technologies in a research note on Monday, February 26th. They set an “outperform” rating and a $18.00 target price for the company. Finally, Jefferies Group began coverage on Sol Gel Technologies in a research note on Monday, February 26th. They set a “buy” rating and a $17.00 target price for the company.
NASDAQ:SLGL opened at $10.39 on Monday. The stock has a market capitalization of $196.61 and a P/E ratio of -3.15. Sol Gel Technologies has a one year low of $8.99 and a one year high of $16.48.
ILLEGAL ACTIVITY WARNING: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/09/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-sol-gel-technologies-slgl-stock-price.html.
About Sol Gel Technologies
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy.
Receive News & Ratings for Sol Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.